A novel phenoxy thiophene sulphonamide molecule protects against glutamate evoked oxidative injury in a neuronal cell model

BMC Neuroscience

Gordon C Ibeanu¹  Eun Y Huh²  Nailya S Gliyazova³ 

[1]Department of Pharmaceutical Sciences, North Carolina Central University, 1801 Fayetteville Street, Durham, NC 27707, USA

[2]Center for Gastrointestinal Biology and Diseases, University of North Carolina, Chapel Hill, NC 27599, USA

[3]BRITE, North Carolina Central University, 1801 Fayetteville Street, Durham, NC 27707, USA

关键词: HT-22;    Phenoxy thiophene;    Neurodegenerative disease;    ERK3;    Oxidative stress;    Alzheimer’s disease;    Small molecule;    Excitotoxicity;    Neuroprotection;    Glutamate;   

Others  :  1140143
DOI  :  10.1186/1471-2202-14-93

 received in 2013-03-05, accepted in 2013-08-29,  发布年份 2013

【 摘 要 】

Background

Glutamate is one of the major neurotransmitters in the central nervous system. It is a potent neurotoxin capable of neuronal destruction through numerous signal pathways when present in high concentration. Glutamate-evoked excitotoxicity has been implicated in the etiology of many neurodegenerative diseases including Alzheimer’s disease (AD), Parkinson’s disease (PD), and ischemic stroke. Increasing evidence has shown that reactive oxygen species (ROS) provoked by glutamate-linked oxidative stress plays a crucial role in the pathogenesis of these disorders. We previously reported the discovery of an aryl thiophene compound, 4-chloro-N-(naphthalen-1-ylmethyl)-5-(3-(piperazin-1-yl)phenoxy)thiophene-2-sulfonamide (B355252) from a proprietary library of small molecules. We showed that this compound was capable of potentiating nerve growth factor (NGF)-primed neurite outgrowth in neuronal cell models in a low NGF environment. In the present study we investigated the neuroprotective effects and signaling pathways of B355252 on glutamate-evoked excitotoxicity in HT-22, a murine hippocampal neuronal cell line.

Results

Glutamate significantly decreased HT-22 neuronal cell viability in a concentration-dependent manner as measured by the MTT assay. Co-treatment with 2, 4, and 8 μM B355252 protected against cell death caused by glutamate-induced toxicity by 9.1% (p<0.01), 26.0% (p<0.001), and 61.9% (p<0.001) respectively, compared to glutamate-treated control group. B355252 at a concentration of 8 μM fully rescued HT-22 from the neurototoxic effects of glutamate, and by itself increased cell viability by 16% (p<0.001) above untreated control. Glutamate enhanced reduction in glutathione (GSH) synthesis was reversed by 15% (p<0.01) in the presence of B355252. B355252 reduced the expression of apoptosis inducing factor (AIF) by 27%, while the proapoptotic Bcl-2 associated X protein (Bax) was strongly attenuated 3-fold. Glutamate-evoked increase in intracellular calcium (Ca²⁺) load and subsequent ROS production was inhibited by 71% (p<0.001) and 40% (p<0.001) respectively, to comparable level as untreated control in the presence of B355252. Glutamate significantly upregulated the phosphorylation of extracellular signal regulated kinase Erk1/2 (pERK1/2), while decreasing Erk3. In contrast, B355252 potently attenuated the glutamate-dependent activation of Erk1/2 and robustly increased the level of ERK3 in HT-22.

Conclusions

A novel phenoxy thiophene small molecule, B355252, suppresses glutamate-evoked oxidative stress in HT-22 neurons by blocking Ca²⁺ and ROS production, and altering the expression or phosphorylation states of Erk kinases. This molecule previously reported to enhance neurite outgrowth in the presence of sub-physiological concentrations of NGF appears to be a promising drug candidate for development as a potential therapeutic and neuroprotective agent for various neurodegenerative disorders.

【 授权许可】

   
2013 Gliyazova et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

Figure 7.

Figure 2.

【 参考文献 】

• [1]Westerberg E, Monaghan DT, Cotman CW, Wieloch T: Excitatory amino acid receptors and ischemic brain damage in the rat. Neurosci Lett 1987, 73(2):119-124.
• [2]Moussawi K, Riegel A, Nair S, Kalivas PW: Extracellular glutamate: functional compartments operate in different concentration ranges. Front Syst Neurosci 2011, 5:94.
• [3]Fayed N, Modrego PJ, Rojas-Salinas G, Aguilar K: Brain glutamate levels are decreased in Alzheimer’s disease: a magnetic resonance spectroscopy study. Am J Alzheimers Dis Other Demen 2011, 26(6):450-456.
• [4]Rupsingh R, Borrie M, Smith M, Wells JL, Bartha R: Reduced hippocampal glutamate in Alzheimer disease. Neurobiol Aging 2011, 32(5):802-810.
• [5]Rainesalo S, Keranen T, Palmio J, Peltola J, Oja SS, Saransaari P: Plasma and cerebrospinal fluid amino acids in epileptic patients. Neurochem Res 2004, 29(1):319-324.
• [6]Miulli DE, Norwell DY, Schwartz FN: Plasma concentrations of glutamate and its metabolites in patients with Alzheimer’s disease. J Am Osteopath Assoc 1993, 93(6):670-676.
• [7]Ilzecka J, Stelmasiak Z, Solski J, Wawrzycki S, Szpetnar M: Plasma amino acids concentration in amyotrophic lateral sclerosis patients. Amino Acids 2003, 25(1):69-73.
• [8]Bleich S, Romer K, Wiltfang J, Kornhuber J: Glutamate and the glutamate receptor system: a target for drug action. Int J Geriatr Psychiatry 2003, 18(Suppl 1):S33-S40.
• [9]Conn PJ: Physiological roles and therapeutic potential of metabotropic glutamate receptors. Ann N Y Acad Sci 2003, 1003:12-21.
• [10]Sattler R, Tymianski M: Molecular mechanisms of glutamate receptor-mediated excitotoxic neuronal cell death. Mol Neurobiol 2001, 24(1–3):107-129.
• [11]Nicholls DG: Mitochondrial dysfunction and glutamate excitotoxicity studied in primary neuronal cultures. Curr Mol Med 2004, 4(2):149-177.
• [12]Ankarcrona M, Dypbukt JM, Orrenius S, Nicotera P: Calcineurin and mitochondrial function in glutamate-induced neuronal cell death. FEBS Lett 1996, 394(3):321-324.
• [13]Murphy TH, Miyamoto M, Sastre A, Schnaar RL, Coyle JT: Glutamate toxicity in a neuronal cell line involves inhibition of cystine transport leading to oxidative stress. Neuron 1989, 2(6):1547-1558.
• [14]Farooqui T, Farooqui AA: Aging: an important factor for the pathogenesis of neurodegenerative diseases. Mech Ageing Dev 2009, 130(4):203-215.
• [15]Shadrina MI, Slominsky PA, Limborska SA: Molecular mechanisms of pathogenesis of Parkinson’s disease. Int Rev Cell Mol Biol 2010, 281:229-266.
• [16]Arundine M, Tymianski M: Molecular mechanisms of glutamate-dependent neurodegeneration in ischemia and traumatic brain injury. Cell Mol Life Sci 2004, 61(6):657-668.
• [17]Fernandez-Checa JC, Fernandez A, Morales A, Mari M, Garcia-Ruiz C, Colell A: Oxidative stress and altered mitochondrial function in neurodegenerative diseases: lessons from mouse models. CNS Neurol Disord: Drug Targets 2010, 9(4):439-454.
• [18]Manzanero S, Santro T, Arumugam TV: Neuronal oxidative stress in acute ischemic stroke: sources and contribution to cell injury. Neurochem Int 2013, 62(5):712-718.
• [19]Onyango IG, Khan SM: Oxidative stress, mitochondrial dysfunction, and stress signaling in Alzheimer’s disease. Curr Alzheimer Res 2006, 3(4):339-349.
• [20]Rawdin BJ, Mellon SH, Dhabhar FS, Epel ES, Puterman E, Su Y, Burke HM, Reus VI, Rosser R, Hamilton SP, et al.: Dysregulated relationship of inflammation and oxidative stress in major depression. Brain Behav Immun 2013, 31:143-152.
• [21]Fleming JL, Phiel CJ, Toland AE: The role for oxidative stress in aberrant DNA methylation in Alzheimer’s disease. Curr Alzheimer Res 2012, 9(9):1077-1096.
• [22]Santos RX, Correia SC, Zhu X, Lee HG, Petersen RB, Nunomura A, Smith MA, Perry G, Moreira PI: Nuclear and mitochondrial DNA oxidation in Alzheimer’s disease. Free Radic Res 2012, 46(4):565-576.
• [23]Butterfield DA, Drake J, Pocernich C, Castegna A: Evidence of oxidative damage in Alzheimer’s disease brain: central role for amyloid beta-peptide. Trends Mol Med 2001, 7(12):548-554.
• [24]Butterfield DA, Castegna A, Lauderback CM, Drake J: Evidence that amyloid beta-peptide-induced lipid peroxidation and its sequelae in Alzheimer’s disease brain contribute to neuronal death. Neurobiol Aging 2002, 23(5):655-664.
• [25]Butterfield DA, Lauderback CM: Lipid peroxidation and protein oxidation in Alzheimer’s disease brain: potential causes and consequences involving amyloid beta-peptide-associated free radical oxidative stress. Free Radic Biol Med 2002, 32(11):1050-1060.
• [26]Alberdi E, Sanchez-Gomez MV, Cavaliere F, Perez-Samartin A, Zugaza JL, Trullas R, Domercq M, Matute C: Amyloid beta oligomers induce Ca2+ dysregulation and neuronal death through activation of ionotropic glutamate receptors. Cell Calcium 2010, 47(3):264-272.
• [27]Ferreira IL, Bajouco LM, Mota SI, Auberson YP, Oliveira CR, Rego AC: Amyloid beta peptide 1–42 disturbs intracellular calcium homeostasis through activation of GluN2B-containing N-methyl-d-aspartate receptors in cortical cultures. Cell Calcium 2012, 51(2):95-106.
• [28]Williams AL, Dandepally SR, Gilyazova N, Witherspoon SM, Ibeanu G: Microwave-assisted synthesis of 4-chloro-N-(naphthalen-1-ylmethyl)-5-(3-(piperazin-10-yl)phenoxy)thiophene-2-sulfonamide (B-355252): a new potentiator of nerve growth factor (NGF)-induced neurite outgrowth. Tetrahedron 2010, 66(50):9577-9581.
• [29]Satoh T, Nakatsuka D, Watanabe Y, Nagata I, Kikuchi H, Namura S: Neuroprotection by MAPK/ERK kinase inhibition with U0126 against oxidative stress in a mouse neuronal cell line and rat primary cultured cortical neurons. Neurosci Lett 2000, 288(2):163-166.
• [30]Fukui M, Song JH, Choi J, Choi HJ, Zhu BT: Mechanism of glutamate-induced neurotoxicity in HT-22 mouse hippocampal cells. Eur J Pharmacol 2009, 617(1–3):1-11.
• [31]Stanciu M, Wang Y, Kentor R, Burke N, Watkins S, Kress G, Reynolds I, Klann E, Angiolieri MR, Johnson JW, et al.: Persistent activation of ERK contributes to glutamate-induced oxidative toxicity in a neuronal cell line and primary cortical neuron cultures. J Biol Chem 2000, 275(16):12200-12206.
• [32]Headley PM, Grillner S: Excitatory amino acids and synaptic transmission: the evidence for a physiological function. Trends Pharmacol Sci 1990, 11(5):205-211.
• [33]Zeng LH, Ouyang Y, Gazit V, Cirrito JR, Jansen LA, Ess KC, Yamada KA, Wozniak DF, Holtzman DM, Gutmann DH, et al.: Abnormal glutamate homeostasis and impaired synaptic plasticity and learning in a mouse model of tuberous sclerosis complex. Neurobiol Dis 2007, 28(2):184-196.
• [34]Le Poul E, Bolea C, Girard F, Poli S, Charvin D, Campo B, Bortoli J, Bessif A, Luo B, Koser AJ, et al.: A potent and selective metabotropic glutamate receptor 4 positive allosteric modulator improves movement in rodent models of Parkinson’s disease. J Pharmacol Exp Ther 2012, 343(1):167-177.
• [35]Farber NB, Newcomer JW, Olney JW: The glutamate synapse in neuropsychiatric disorders. Focus on schizophrenia and Alzheimer’s disease. Prog Brain Res 1998, 116:421-437.
• [36]Kulawiak B, Szewczyk A: Glutamate-induced cell death in HT-22 mouse hippocampal cells is attenuated by paxilline, a BK channel inhibitor. Mitochondrion 2012, 12(1):169-172.
• [37]Tan S, Schubert D, Maher P: Oxytosis: a novel form of programmed cell death. Curr Top Med Chem 2001, 1(6):497-506.
• [38]Xu XS, Chua CC, Zhang M, Geng DQ, Liu CF, Hamdy RC, Chua BHL: The role of PARP activation in glutamate-induced necroptosis in HT-22 cells. Brain Res 2010, 1343:206-212.
• [39]Culmsee C, Zhu CL, Landshamer S, Becattini B, Wagner E, Pellechia M, Blomgren K, Plesnila N: Apoptosis-inducing factor triggered by poly(ADP-ribose) polymerase and bid mediates neuronal cell death after oxygen-glucose deprivation and focal cerebral ischemia. J Neurosci 2005, 25(44):10262-10272.
• [40]Xu XS, Chua CC, Kong JM, Kostrzewa RM, Kumaraguru U, Hamdy RC, Chua BHL: Necrostatin-1 protects against glutamate-induced glutathione depletion and caspase-independent cell death in HT-22 cells. J Neurochem 2007, 103(5):2004-2014.
• [41]Zhang Y, Lu X, Bhavnani BR: Equine estrogens differentially inhibit DNA fragmentation induced by glutamate in neuronal cells by modulation of regulatory proteins involved in programmed cell death. BMC Neurosci 2003, 4:32. BioMed Central Full Text
• [42]Iriyama T, Kamei Y, Kozuma S, Taketani Y: Bax-inhibiting peptide protects glutamate-induced cerebellar granule cell death by blocking Bax translocation. Neurosci Lett 2009, 451(1):11-15.
• [43]Gao M, Zhang WC, Liu QS, Hu JJ, Liu GT, Du GH: Pinocembrin prevents glutamate-induced apoptosis in SH-SY5Y neuronal cells via decrease of bax/bcl-2 ratio. Eur J Pharmacol 2008, 591(1–3):73-79.
• [44]McConkey DJ, Orrenius S: The role of calcium in the regulation of apoptosis. Biochem Biophys Res Commun 1997, 239(2):357-366.
• [45]Budd SL, Nicholls DG: Mitochondria, calcium regulation, and acute glutamate excitotoxicity in cultured cerebellar granule cells. J Neurochem 1996, 67(6):2282-2291.
• [46]Davis JB, Maher P: Protein kinase C activation inhibits glutamate-induced cytotoxicity in a neuronal cell line. Brain Res 1994, 652(1):169-173.
• [47]Tobaben S, Grohm J, Seiler A, Conrad M, Plesnila N, Culmsee C: Bid-mediated mitochondrial damage is a key mechanism in glutamate-induced oxidative stress and AIF-dependent cell death in immortalized HT-22 hippocampal neurons. Cell Death Differ 2011, 18(2):282-292.
• [48]Davis RJ: The mitogen-activated protein kinase signal transduction pathway. J Biol Chem 1993, 268(20):14553-14556.
• [49]Luo Y, DeFranco DB: Opposing roles for ERK1/2 in neuronal oxidative toxicity: distinct mechanisms of ERK1/2 action at early versus late phases of oxidative stress. J Biol Chem 2006, 281(24):16436-16442.
• [50]Namura S, Iihara K, Takami S, Nagata I, Kikuchi H, Matsushita K, Moskowitz MA, Bonventre JV, Alessandrini A: Intravenous administration of MEK inhibitor U0126 affords brain protection against forebrain ischemia and focal cerebral ischemia. Proc Natl Acad Sci U S A 2001, 98(20):11569-11574.
• [51]Wang JQ, Fibuch EE, Mao L: Regulation of mitogen-activated protein kinases by glutamate receptors. J Neurochem 2007, 100(1):1-11.
• [52]Julien C, Coulombe P, Meloche S: Nuclear export of ERK3 by a CRM1-dependent mechanism regulates its inhibitory action on cell cycle progression. J Biol Chem 2003, 278(43):42615-42624.
• [53]Hansen CA, Bartek J, Jensen S: A functional link between the human cell cycle-regulatory phosphatase Cdc14A and the atypical mitogen-activated kinase Erk3. Cell Cycle 2008, 7(3):325-334.
• [54]Boulton TG, Nye SH, Robbins DJ, Ip NY, Radziejewska E, Morgenbesser SD, DePinho RA, Panayotatos N, Cobb MH, Yancopoulos GD: ERKs: a family of protein-serine/threonine kinases that are activated and tyrosine phosphorylated in response to insulin and NGF. Cell 1991, 65(4):663-675.
• [55]Turgeon B, Saba-El-Leil MK, Meloche S: Cloning and characterization of mouse extracellular-signal-regulated protein kinase 3 as a unique gene product of 100 kDa. Biochem J 2000, 346(Pt 1):169-175.
• [56]Brand F, Schumacher S, Kant S, Menon MB, Simon R, Turgeon B, Britsch S, Meloche S, Gaestel M, Kotlyarov A: The extracellular signal-regulated kinase 3 (mitogen-activated protein kinase 6 [MAPK6])-MAPK-activated protein kinase 5 signaling complex regulates septin function and dendrite morphology. Mol Cell Biol 2012, 32(13):2467-2478.